Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002013791 | SCV002307426 | uncertain significance | Acrocallosal syndrome | 2022-06-13 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 979 of the KIF7 protein (p.Glu979Lys). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with KIF7-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004982845 | SCV005611573 | uncertain significance | Inborn genetic diseases | 2024-12-03 | criteria provided, single submitter | clinical testing | The c.2935G>A (p.E979K) alteration is located in exon 15 (coding exon 14) of the KIF7 gene. This alteration results from a G to A substitution at nucleotide position 2935, causing the glutamic acid (E) at amino acid position 979 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005008409 | SCV005642888 | uncertain significance | Acrocallosal syndrome; Multiple epiphyseal dysplasia, Al-Gazali type; Hydrolethalus syndrome 2 | 2024-01-16 | criteria provided, single submitter | clinical testing |